A recent systematic review shows evidence that sFlt-1, PlGF, IL-6, IL-6/IL-10 ratios are interesting candidate biomarkers for cardiovascular risk stratification after PE or HELLP syndrome (hemolysis, elevated liver enzymes and low platelets) [14]. The gene discussed is IL6; the disease is HELLP syndrome.